You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) Antibodies

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. Additionally we are shipping VHL Kits (10) and VHL Proteins (7) and many more products for this protein.

list all antibodies Gene Name GeneID UniProt
VHL 22346 P40338
VHL 7428 P40337
VHL 24874 Q64259
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top anti-VHL Antibodies at antibodies-online.com

Showing 10 out of 113 products:

Catalog No. Reactivity Host Conjugate Application Images Quantity Supplier Delivery Price Details
Human Mouse Un-conjugated EIA, IHC (p), WB Western blot analysis.,.HepG2 cell lysate was resolved by SDS-PAGE, transferred to PVDF membrane and probed with anti-human VHL antibody (1:500). Protein was visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system. 0.1 mL Log in to see 6 to 8 Days
$412.50
Details
Human Mouse Un-conjugated IHC (fro), IHC (p), IP, WB 0.1 mg Log in to see 6 to 8 Days
$654.50
Details
Human Goat Un-conjugated ELISA, WB ABIN185675 (0.01 ug/ml) staining of Human Ovary lysate (35 ug protein in RIPA buffer).  Primary incubation was 1 hour.  Detected by chemiluminescence. 100 μg Log in to see 4 to 5 Days
$326.89
Details
Human Rabbit Un-conjugated EIA, WB Western blot analysis of VHL antibody (C-term) in HepG2 cell line lysates (35ug/lane). VHL (arrow) was detected using the purified Pab. 0.4 mL Log in to see 6 to 8 Days
$390.50
Details
Human Rabbit Un-conjugated EIA, WB Western blot analysis of VHL antibody (N-term) in HepG2 cell line lysates (35ug/lane). VHL (arrow) was detected using the purified Pab. 0.4 mL Log in to see 6 to 8 Days
$401.50
Details
Human Rabbit Un-conjugated IHC, ELISA Immunohistochemistry analysis of paraffin-embedded human brain tissue, using VHL (Ab-68) Antibody. The picture on the right is treated with the synthesized peptide. 100 μg Log in to see 2 to 3 Days
$302.50
Details
Dog Goat Un-conjugated EIA, WB 0.1 mg Log in to see 6 to 8 Days
$379.50
Details
Human Mouse Un-conjugated IHC (f), IP, WB VHL Immunohistochemical staining on human renal cell carcinoma. Formalin fixed paraffin embedded human renal cell carcinoma was pretreated with BD Retrervagen A and then stained with either Purified Mouse IgG1, kappa isotype control (Clone MOPC-21, First Panel) or Purified Mouse anti-VHL (Second Panel). Stained with purified Mouse anti-VHL. 0.1 mg Log in to see 5 to 6 Days
$199.15
Details
Human Mouse Un-conjugated ELISA, WB Detection limit for recombinant GST tagged VHL is approximately 0.1 ng/mL as a capture antibody. 0.1 mg Log in to see 8 to 11 Days
$450.00
Details
Human Rabbit Un-conjugated FACS, IF, IHC (p), WB Western blot analysis of VHL antibody (N-term) (ABIN390462) in HepG2 cell line lysates (35 µg/lane). VHL (arrow) was detected using the purified polyclonal antibody. VHL Antibody (N-term) (ABIN390462) IHC analysis in formalin fixed and paraffin embedded human brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining 400 μL Log in to see 10 to 11 Days
$324.50
Details

VHL Antibodies by Reactivity, Application, Clonality and Conjugate

Attributes Applications Host Clonality Conjugate
Mouse (Murine) , , ,
, ,
,
, , , , , , , , , , , , ,
Human , , , ,
, ,
,
, , , , , , , , , , , , , , , , , , ,
Rat (Rattus) , , ,
, ,
,
, , , , , , , , , , , , , , , ,

Top referenced anti-VHL Antibodies

  1. Human Monoclonal VHL Primary Antibody for IHC (f), IP - ABIN967508 : Baba, Hirai, Kawakami, Kishida, Sakai, Kaneko, Yao, Shuin, Kubota, Hosaka, Ohno: Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth. in Oncogene 2001 (PubMed)
    Show all 7 references for ABIN967508

  2. Human Monoclonal VHL Primary Antibody for ELISA, WB - ABIN393528 : Peña, Lathia, Shan, Escudier, Bukowski: Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. in Clinical cancer research : an official journal of the American Association for Cancer Research 2010 (PubMed)
    Show all 5 references for ABIN393528

  3. Human Monoclonal VHL Primary Antibody for IHC (fro), IHC (p) - ABIN264443 : Los, Jansen, Kaelin, Lips, Blijham, Voest: Expression pattern of the von Hippel-Lindau protein in human tissues. in Laboratory investigation; a journal of technical methods and pathology 1996 (PubMed)
    Show all 4 references for ABIN264443

  4. Human Polyclonal VHL Primary Antibody for EIA, WB - ABIN453458 : Olmos, Arenas, Bienes, Calzada, Aragonés, Garcia-Bermejo, Landazuri, Lucio-Cazaña: 15-Deoxy-Delta(12,14)-prostaglandin-J(2) reveals a new pVHL-independent, lysosomal-dependent mechanism of HIF-1alpha degradation. in Cellular and molecular life sciences : CMLS 2009 (PubMed)
    Show all 3 references for ABIN453458

  5. Human Polyclonal VHL Primary Antibody for EIA, WB - ABIN453457 : Hatzimichael, Dranitsaris, Dasoula, Benetatos, Stebbing, Crook, Bourantas: Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease. in Clinical lymphoma & myeloma 2009 (PubMed)
    Show all 3 references for ABIN453457

  6. Human Polyclonal VHL Primary Antibody for ELISA, WB - ABIN185675 : Kong, Lin, Liang, Fath, Sang, Caro: Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. in Molecular and cellular biology 2006 (PubMed)

  7. Human Monoclonal VHL Primary Antibody for EIA, IHC (p) - ABIN121157 : Staller, Sulitkova, Lisztwan, Moch, Oakeley, Krek: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. in Nature 2003 (PubMed)

  8. Human Polyclonal VHL Primary Antibody for IHC, ELISA - ABIN1533202 : Latif, Tory, Gnarra, Yao, Duh, Orcutt, Stackhouse, Kuzmin, Modi, Geil: Identification of the von Hippel-Lindau disease tumor suppressor gene. in Science (New York, N.Y.) 1993 (PubMed)

More Antibodies against VHL Interaction Partners

Mouse (Murine) Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) interaction partners

  1. Loss of Vhl in mesenchymal progenitors of the limb bud caused severe fibrosis of the synovial joints and formation of aggressive masses with histologic features of mesenchymal tumors.

  2. These data suggested that intestinal epithelial cells were injured after IM treatment through the pVHL overexpression-induced degradation of collagen I or HIF-1alpha (show HIF1A Antibodies).

  3. Vhl and Kif3a (show KIF3A Antibodies) deletion accelerates renal cyst formation

  4. maintains the stability and suppressive function of Foxp3 (show FOXP3 Antibodies)+ T cells via regulation of HIF-1a (show HIF1A Antibodies) pathway

  5. Deletion of the Vhl gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.

  6. Molecular dynamics of hif-1alpha (show HIF1A Antibodies) and VHL may determine the success of antineoplastic strategies in hypoxia-reoxygenation as predicted by computational modeling.

  7. Loss of Vhl in adult joint cartilage is associated with earlier dysregulation of cartilage homeostasis, characterized by increased chondrocyte apoptosis, compromised chondrocyte autophagy and accelerated age-related and surgery-induced OA development.

  8. Both Vhl and Bap1 (show BAP1 Antibodies) are required for kidney function. Even when Vhl is inactivated in multipotent nephron progenitor cells, Vhl loss is insufficient for renal tumorigenesis.

  9. VHL deficiency perturbs pancreas endocrine homeostasis in mice.

  10. data suggest that the VHL-mediated signaling in osteochondral progenitor cells plays a critical role in bone remodeling at postnatal/adult stages through coupling osteogenesis and angiogenesis

Human Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL) interaction partners

  1. These findings demonstrated that VHL and P53 (show TP53 Antibodies) act synergistically in the regulation of cell proliferation and apoptosis in CCRCC. Overall, VHL and P53 (show TP53 Antibodies) have important roles in the regulation of cell proliferation and apoptosis in CCRCC

  2. Our aim was to identify VHL gene mutations in Argentinian patients who fulfilled the clinical criteria for type 1 VHL disease and in patients with VHL-associated manifestations. VHL mutations were detected in 16/19 (84.2%) patients in Group 1 and included: gross deletions (4/16); nonsense mutations (6/16); frameshift mutations (4/16); missense mutations (1/16); and splicing mutations (1/16). Three mutations were novel.

  3. Mutations in the VHL gene is associated with von Hippel-Lindau syndrome.

  4. The von Hippel-Lindau protein (show VHLL Antibodies) (pVHL) bound directly to hydroxylated Akt (show AKT1 Antibodies) and inhibited Akt (show AKT1 Antibodies) activity.

  5. VHL-deficient renal cancer cells gain resistance to mitochondria-activating apoptosis inducers by activating AKT (show AKT1 Antibodies) through the IGF1R (show IGF1R Antibodies)-PI3K (show PIK3CA Antibodies) pathway

  6. VHL promoter hypermethylation, which may play an important role in carcinogenesis of renal cell carcinoma (show MOK Antibodies) (RCC (show XRCC1 Antibodies)), is significantly associated with an increased risk of RCC (show XRCC1 Antibodies).

  7. VHLalpha isoform inhibits Warburg effect via modulation of PKM splicing.

  8. The VHL short variant is involved in protein quality control during translation.

  9. Study identified VHL as a direct target of miR (show MLXIP Antibodies)-101 and demonstrated that miR (show MLXIP Antibodies)-101 could increase HIF1alpha (show HIF1A Antibodies) protein levels by repressing VHL in normoxia condition.

  10. VHL inactivation is associated with gastrointestinal stromal tumors.

VHL Antigen Profile

Protein Summary

Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.

Gene names and symbols associated with VHL

  • von Hippel-Lindau tumor suppressor (Vhl) antibody
  • von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (VHL) antibody
  • von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (Vhl) antibody
  • HRCA1 antibody
  • pVHL antibody
  • RCA1 antibody
  • VHL1 antibody
  • Vhlh antibody

Protein level used designations for VHL

pVHL , von Hippel-Lindau disease tumor suppressor , von Hippel-Lindau syndrome homolog , von Hippel-Lindau syndrome protein homolog , elongin binding protein , protein G7

GENE ID SPECIES
22346 Mus musculus
7428 Homo sapiens
24874 Rattus norvegicus
494000 Canis lupus familiaris
Selected quality suppliers for anti-VHL (VHL) Antibodies
Did you look for something else?